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ABSTRACT 
Angiogenesis is the formation of new blood vessels from pre-existing vessels. It is highly 
regulated in a normal physiological system. Dysregulated angiogenesis is associated with a 
a number of pathological states such as cancer and rheumatoid arthritis. Thus angiogenesis 
is proposed as a target for control of such diseases. The identification of novel genes 
involved in angiogenesis will improve the likelihood of the development of efficacious 
drugs. 
To identify genes essential to angiogenesis, we used an in vitro model of capillary tube 
formation and a PCR based subtraction hybridisation approach for isolation of regulated 
genes. We identified 125 different genes including 96 known and 29 novel genes and of 
these, 84 genes were confirmed to be regulated during the formation of capillary tubes. 
From the 125 isolated genes, one novel gene displayed characteristics suitable for further 
investigation. The gene, p73RhoGAP is a new member of the RhoGAP family. It is highly 
upregulated at 3 and 6 h in the tube formation process but only in an angiogenic milieu 
with little or no regulation seen under non-angiogenic conditions, and is restricted in its 
expression to vascular cells. Thus, we propose that p73RhoGAP is called V ASGAP. 
Bioinformatics analysis of the protein sequence revealed the presence of a putative 
Rho GAP domain, indicating a potential role in the activation of RhoGTPases. Our study 
suggests that VASGAP displays RhoGAP activity for Rho but not Rac or Cdc42. 
RhoGTPase activity assays demonstrated that mutation of the conserved arginine at residue 
82 (R82A) in the RhoGAP domain is crucial to the p73 effect on Rho. V ASGAP localises 
to actin stress fibres. 
To characterise the function of VASGAP, knockdown of the protein was achieved by 
adenovirus delivery of V ASGAP antisense into EC. Such V ASGAP depleted cells showed 
enhanced actin stress fibres and basal permeability consistent with alteration of Rho 
activity. Cell migration, proliferation and capillary tube formation were inhibited, and 
enhanced apoptosis was evident. In an in vivo model of angiogenesis, antisense of 
V ASGAP inhibited blood vessel invasion. 
Thus, the results suggest V AS GAP is an important and novel modulator of angiogenesis 
and cell survival and displays many of the features worthy of a drug target. 
